Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer

被引：4

作者：

Gagno, Sara ^{[1
]}

Bartoletti, Michele ^{[2
,3
]}

Romualdi, Chiara ^{[4
]}

Poletto, Elena ^{[5
]}

Scalone, Simona ^{[3
]}

Sorio, Roberto ^{[3
]}

Zanchetta, Martina ^{[1
]}

De Mattia, Elena ^{[1
]}

Roncato, Rossana ^{[1
]}

Cecchin, Erika ^{[1
]}

Giorda, Giorgio ^{[6
]}

Toffoli, Giuseppe ^{[1
]}

机构：

[1] IRCCS, Ctr Riferimento Oncol Aviano CRO, Expt & Clin Pharmacol Unit, Via Franco Gallini 2, I-33081 Aviano, Italy

[2] Univ Udine, Dept Med DAME, Via Palladio 8, I-33100 Udine, Italy

[3] IRCCS, Ctr Riferimento Oncol Aviano CRO, Dept Med Oncol, Via Franco Gallini 2, I-33081 Aviano, Italy

[4] Univ Padua, Dept Biol, Via Ugo Bassi 58 B, I-35122 Padua, Italy

[5] ASUI Udine Univ Hosp, Dept Oncol, Via Pozzuolo 330, I-33100 Udine, Italy

[6] IRCCS, Ctr Riferimento Oncol CRO Aviano, Gynaecol Oncol Unit, Via Franco Gallini 2, I-33081 Aviano, Italy

来源：

PHARMACOGENOMICS | 2020年 / 21卷 / 14期

关键词：

estrogen; ovarian cancer; pharmacogenetics; platinum therapy; polymorphism; survival; GENETIC POLYMORPHISMS; NONCODING RNA; CHEMOTHERAPY; RISK; RESISTANCE; VARIANTS; BREAST; ASSOCIATION; PROTEIN; EXPRESSION;

D O I：

10.2217/pgs-2020-0049

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim:To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP).Patients & Methods:Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival (OS), progression-free survival (PFS) and platinum-free interval (PFI).Results:ABCG2rs3219191D>I,UGT1Ars10929302G>A andUGT1Ars2741045T>C polymorphisms were significantly associated with all three parameters (OS, PFS and PFI) and were used to generate a score. Patients in high-risk group had a poorer OS (hazard ratio [HR]: 1.8; 95% CI: 1.3-2.7; p = 0.0019), PFS (HR: 2.0; 95% CI: 1.4-2.9; p < 0.0001) and PFI (HR: 1.9; 95% CI: 1.4-2.8; p = 0.0002) compared with those in low-risk group.Conclusion:The prognostic-score including polymorphisms involved in drug and estrogen pathways stratifies OCP according to OS, PFS and PFI.

引用

页码：995 / 1010

页数：16

共 44 条

[1] Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].

Amirimani, B ;

Ning, B ;

Deitz, AC ;

Weber, BL ;

Kadlubar, FF ;

Rebbeck, TR .

ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 42 (04) :299-305

[2] Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis [J].

Assis, Joana ;

Pereira, Carina ;

Nogueira, Augusto ;

Pereira, Deolinda ;

Carreira, Rafael ;

Medeiros, Rui .

CANCER TREATMENT REVIEWS, 2017, 61 :35-52

[3]

Assis J, 2013, INT J CLIN EXP MED, V6, P552

[4] PharmGKB summary: very important pharmacogene information for UGT1A1 [J].

Barbarino, Julia M. ;

Haidar, Cyrine E. ;

Klein, Teri E. ;

Altman, Russ B. .

PHARMACOGENETICS AND GENOMICS, 2014, 24 (03) :177-183

[5] Serum bilirubin concentration is modified by UGT1A1 Haplotypes and influences risk of Type-2 diabetes in the Norfolk Island genetic isolate [J].

Benton, M. C. ;

Lea, R. A. ;

Macartney-Coxson, D. ;

Bellis, C. ;

Carless, M. A. ;

Curran, J. E. ;

Hanna, M. ;

Eccles, D. ;

Chambers, G. K. ;

Blangero, J. ;

Griffiths, L. R. .

BMC GENETICS, 2015, 16

[6]

Cecchin E, 2004, ONCOL REP, V12, P457

[7] ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease [J].

Colombo, N. ;

Sessa, C. ;

du Bois, A. ;

Ledermann, J. ;

McCluggage, W. G. ;

McNeish, I. ;

Morice, P. ;

Pignata, S. ;

Ray-Coquard, I. ;

Vergote, I. ;

Baert, T. ;

Belaroussi, I. ;

Dashora, A. ;

Olbrecht, S. ;

Planchamp, F. ;

Querleu, D. ;

Banerjee, S. ;

Blecharz, P. ;

Bruchim, I. ;

Cibula, D. ;

Concin, N. ;

Davidson, B. ;

Devouassoux-Shisheboran, M. ;

Ferrero, A. ;

Glasspool, R. ;

Gonzalez-Martin, A. ;

Heinzelmann-Schwarz, V. ;

Joly, F. ;

Kim, J. W. ;

Kridelka, F. ;

Lorusso, D. ;

Mahner, S. ;

Mikami, M. ;

Mirza, M. R. ;

Nicum, S. ;

O'Donnell, D. M. ;

Pautier, P. ;

Rodolakis, A. ;

Sehouli, J. ;

Selcukbiricik, F. ;

Singh, N. ;

Tan, D. S. P. ;

Timmerman, D. ;

Tognon, G. ;

van der Velden, J. ;

Witteveen, P. O. ;

Zeimet, A. G. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) :728-760

[8] Genome-Wide Association Study (GWAS) on Bilirubin Concentrations in Subjects with Metabolic Syndrome: Sex-Specific GWAS Analysis and Gene-Diet Interactions in a Mediterranean Population [J].

Coltell, Oscar ;

Asensio, Eva M. ;

Sorli, Jose V. ;

Barragan, Rocio ;

Fernandez-Carrion, Rebeca ;

Portoles, Olga ;

Ortega-Azorin, Carolina ;

Martinez-LaCruz, Raul ;

Gonzalez, Jose I. ;

Zanon-Moreno, Vicente ;

Gimenez-Alba, Ignacio ;

Fito, Montserrat ;

Ros, Emilio ;

Ordovas, Jose M. ;

Corella, Dolores .

NUTRIENTS, 2019, 11 (01)

[9] UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population [J].

De Mattia, Elena ;

Cecchin, Erika ;

Polesel, Jerry ;

Lupo, Francesco ;

Tiribelli, Claudio ;

Crovatto, Marina ;

Buonadonna, Angela ;

Toffoli, Giuseppe .

LIVER INTERNATIONAL, 2017, 37 (09) :1345-1353

[10] Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review [J].

Diaz-Padilla, Ivan ;

Amir, Eitan ;

Marsh, Sharon ;

Liu, Geoffrey ;

Mackay, Helen .

GYNECOLOGIC ONCOLOGY, 2012, 124 (02) :354-365

← 1 2 3 4 5 →